Detail akcie AtriCure online

Business Summary: AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, AtriCure Inc revenues increased 21% to $399.2M. Net loss decreased 34% to $30.4M. Revenues reflect Appendage Management segment increase of 19% to $134.5M, Open-Heart Ablation segment increase of 22% to $105.3M, United States segment increase of 20% to $333.5M, Europe segment increase of 26% to $38.5M. Lower net loss reflects Interest Income increase of 90% to $3.8M (income).